Jonathan S. Leventhal

Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy

Veronica Shi, Nemanja Rodić, Scott Gettinger et al. · JAMA Dermatology · 2016 · 233 citations · Full text

Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy

Jacob Siegel, Mariam Totonchy, William Damsky et al. · Journal of the American Academy of Dermatology · 2018 · 200 citations

Bullous Disorders, Lymphoid Neoplasia, Anti–pd-l1 Therapy +7

Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management

Emily Coleman, Christine J. Ko, Feng Dai et al. · Journal of the American Academy of Dermatology · 2018 · 178 citations

Inflammation, Immune Evasion, Cancer Immunosurveillance +11

Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy

Lihi Atzmony, Young Hee Lim, Claire Hamilton et al. · Journal of the American Academy of Dermatology · 2019 · 132 citations · Full text

Ophthalmology, Medicine, Topical Cholesterol/lovastatin +6

Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare

William Damsky, Durga Thakral, Meaghan K. McGeary et al. · Journal of the American Academy of Dermatology · 2019 · 128 citations · Full text

Inflammation, Autoimmune Disease, Melanoma +9